Management of Kaposiform Haemangioendothelioma—A Retrospective Case Series Examining the Use and Effectiveness of Vincristine
Journal of Paediatrics and Child Health · 2026-08 · 62 (8) · 1450-1457
DOI: 10.1111/jpc.70461 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Paediatrics and Child Health, online erschienen am 05.06.2026. Verfasst von Bronwen Kirk und 4 weiteren Autor:innen. Beteiligte Einrichtung: John Hunter Children's Hospital, New Lambton Heights, New South Wales, Australia. Hauptthemen laut MEDLINE: Vincristine, Hemangioendothelioma, Kasabach-Merritt Syndrome, Sarcoma, Kaposi. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aim
Kaposiform haemangioendothelioma is a rare vascular tumour. Management has evolved over the last two decades, with most cases receiving vincristine or sirolimus. We aim to describe our experience with managing this tumour, with a focus on the safety and efficacy of vincristine.
Methods
A retrospective cohort study of all cases treated at Sydney Children's Hospital over a 19‐year period was conducted. Explanatory variables included age, tumour location, imaging, the presence of Kasabach‐Merrit Phenomenon, and treatment modality. The primary outcome was disease recurrence and the secondary outcome, complications.
Results
Twenty‐one cases were identified with 13 (60%) presenting as neonates. The most common site was limb; and imaging included ultrasound (7/21, 33%) and MRI (12/21, 57%). Almost all had consumptive coagulopathy (20/21, 95%) with 6/21 (29%) having severe Kasabach‐Merrit Phenomenon. Six tumours were excised and 16 (76%) were treated with vincristine, with three (14%) progressing to treatment with sirolimus. There were no recurrences. Complications of vincristine therapy were common but mild in most cases, with only one proven blood stream infection and one requiring central line replacement.
Conclusion
Vincristine remains a highly effective first‐line treatment for kaposiform haemangioendothelioma with an acceptable safety profile. Further well‐designed multicentre trials are needed to objectively compare its effectiveness and safety with sirolimus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- John Hunter Children's Hospital, New Lambton Heights, New South Wales, Australia.
- School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia.
- Vascular Tumours and Anomalies Clinic, Minderoo Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.
- Women's Health, Paediatrics and Child Health, School of Clinical Medicine, University of New South Wales, Kensington, New South Wales, Australia.
ORCID-Profile: Bronwen Kirk, Susan Adams, Orli Wargon, Artiene Tatian
Zitieren
APA
Kirk, B., Adams, S., Wargon, O., Tatian, A., & Russell, S. (2026). Management of Kaposiform Haemangioendothelioma—A Retrospective Case Series Examining the Use and Effectiveness of Vincristine. Journal of Paediatrics and Child Health, 62(8), 1450-1457. https://doi.org/10.1111/jpc.70461
Vancouver
Kirk B, Adams S, Wargon O, Tatian A, Russell S. Management of Kaposiform Haemangioendothelioma—A Retrospective Case Series Examining the Use and Effectiveness of Vincristine. Journal of Paediatrics and Child Health. 2026;62(8):1450-1457. doi:10.1111/jpc.70461
BibTeX
@article{Kirk2026,
author = {Kirk, Bronwen and Adams, Susan and Wargon, Orli and Tatian, Artiene and Russell, Susan},
title = {Management of Kaposiform Haemangioendothelioma—A Retrospective Case Series Examining the Use and Effectiveness of Vincristine},
journal = {Journal of Paediatrics and Child Health},
year = {2026},
volume = {62},
number = {8},
pages = {1450--1457},
doi = {10.1111/jpc.70461}
}
EUVIMED